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OBJECTIVES The study was designed to comprehensively evaluate the circadian effects of aldosterone
blockade on autonomic tone and QT dispersion in chronic heart failure (CHF).
BACKGROUND Spironolactone therapy given in addition to angiotensin-converting enzyme inhibitors
improved survival in CHF, but the mechanism of its benefit is uncertain. Experimental
evidence suggests that aldosterone may have detrimental effects on the autonomic nervous
system, especially during the morning hours.
METHODS Twenty-eight patients with New York Heart Association class II to IV CHF received
spironolactone 50 mg daily and placebo for four weeks each in a double-blind crossover
fashion. After each treatment phase, a full circadian assessment was undertaken of spirono-
lactone’s autonomic effects. The assessment included monitoring heart rate, QT dispersion,
continuous Holter recordings, heart rate variability (HRV) and norepinephrine kinetics.
RESULTS Spironolactone significantly reduced all indices of QT dispersion. The reductions in QTcmax,
QTd and QTcd were greatest at 6 AM. In addition, spironolactone had favorable autonomic
effects, which were limited to the morning (6–10 AM), including heart rate reduction and an
improvement in HRV.
CONCLUSIONS Spironolactone reduced heart rate and improved HRV and QT dispersion in CHF. Its effects
were particularly prominent during the morning hours. (J Am Coll Cardiol 2001;37:1800–7)
© 2001 by the American College of Cardiology
Despite the introduction of angiotensin-converting enzyme
(ACE) inhibitors, mortality rates remain high in chronic
heart failure (CHF) (1–3). This may be partly attributed to
the fact that neurohormonal suppression of the renin-
angiotensin-aldosterone system by long-term ACE inhibi-
tion is inadequate. The suppressive effect of long-term ACE
inhibitors on aldosterone is weak, variable and unsustained
(4,5). The clinical significance of these residual levels of
aldosterone was recently highlighted in the multicenter
Randomized Aldactone Evaluation Study (RALES), where
a 30% reduction in mortality was demonstrated in those
patients with CHF who received the aldosterone antagonist
spironolactone, compared with those receiving placebo (6).
Elevated aldosterone levels in CHF may be harmful for a
number of reasons, including the recently recognized phe-
nomenon that aldosterone may have a detrimental effect on
the autonomic nervous system. First, Wang et al. found that
aldosterone infusion directly reduced baroreceptor discharge
from the carotid sinus in dogs (7). Second, we have recently
shown that aldosterone blunts the human baroreflex re-
sponse (8). Third, aldosterone may potentiate the effects of
catecholamines (9). Aldosterone has been shown to block
myocardial uptake of norepinephrine (NA) in vivo in an
animal model (10). Furthermore, in patients with CHF, the
addition of spironolactone was found to increase myocardial
NA uptake by metaiodobenzylguanidine (MIBG) scanning
(10). Finally, we recently observed that spironolactone also
improved the time-domain measures of heart rate variability
(HRV) in CHF (11).
Intriguingly, aldosterone secretion (12,13) and the auto-
nomic nervous system (14,15) exhibit a circadian variation,
with both increasing in the early morning. This early-
morning peak in aldosterone and sympathetic activity occurs
at the same time as cardiac events peak (16–18). Hence, the
hypothesis arises that the dawn surge in aldosterone may
unfavorably modulate the sympathovagal balance, which
then contributes to the high incidence of cardiac arrhyth-
mias (16), ischemia (17) and sudden deaths (18) seen
particularly during these early hours. In this study, we
carried out a full circadian assessment of the influence of
aldosterone blockade on sympathovagal balance. In addi-
tion, we investigated the effects on cardiac arrhythmias and
the circadian variation of QT dispersion indices. The effect
of aldosterone on the QT interval dispersion (QTd), which
is the difference between the longest and shortest QT
interval measured on the 12-lead electrocardiogram (ECG),
is of particular interest because it has recently been identi-
fied as a sensitive predictor of sudden cardiac death (SCD)
(19–21).
METHODS
Subjects and protocol. Twenty-eight patients with CHF
(New York Heart Association [NYHA] class II to IV) and
left ventricular ejection fraction #40% were recruited from
the CHF clinic of our institute. All patients gave informed
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written consent, and the protocol was approved by the local
Tayside Ethics Committee on Medical Research. The
baseline demographic characteristics are listed in Table 1.
All patients were on optimal therapy and had been treated
with a diuretic and ACE inhibitor for at least six weeks.
Left ventricular ejection fraction was measured by either
echocardiography or radionuclide ventriculography. We ex-
cluded subjects whose predominant cardiac rhythm was not
sinus or who had a bundle branch block or paced complexes
on the ECG. All cardioactive drugs were unchanged during
the study.
All patients were recruited into a double-blind, random-
ized crossover study. Baseline hemodynamic, biochemical
and ECG measurements were obtained before each patient
was randomized to receive spironolactone 50 mg daily or
placebo for a one-month period for each treatment. Be-
tween each treatment, there was a washout period of 30
days. Patients were reviewed weekly for clinical evaluation
of tolerability and biochemical measurements.
At the end of each treatment phase, the patients were
admitted to our research unit and studied over 24 h. All
patients had two intravenous 18G indwelling cannulae
inserted (one in each forearm) and a 24-hr continuous
Holter monitor attached to their chest. After 30 min of bed
rest, baseline values of blood pressure and heart rate were
determined in triplicate using a semi-automatic sphygmo-
manometer (Dinamap, Critikon, Tampa, Florida).
Repeated ECGs and venous blood samples (10 ml) for
plasma NA were obtained at the following time points:
1500 h, 1700 h, 2300 h, 0300 h, 0600 h, 0700 h, 0800 h and
1100 h. The patients were asked to lie supine for 30 min
before each time point. In addition, at 1600 h and 0700 h
the patients were administered an intravenous infusion of
1-(2,5,6-H)-NA for assessment of NA kinetics.
Between the study time points, the patients were allowed
to sit or move about the bedside. Excessive movements were
kept to a minimum, and patients were instructed to record
all their movements. Bedtime and mealtimes were standard-
ized as follows: breakfast 0930 h, lunch 1300 h, dinner
1830 h and bedtime 2300 to 0700 h.
Continuous ECG monitoring and heart rate variability
analysis. Twenty-four hour continuous ECG recordings
were obtained for analysis in all subjects using a standard
two-channel (four leads) Tracker 2 analog tape recorder
(Reynolds, Hertford, United Kingdom) recording standard
leads CM1 and CM5.
Semiautomatic analysis of arrhythmias was performed
using the Pathfinder 500 Series analyzer system (Reynolds,
Hertford, United Kingdom). In addition, the recordings
were also visually checked, and RR intervals and QRS
configuration manually edited, to ensure correct arrhythmia
recognition and classification. Heart rate variability was
assessed according to standardized guidelines (22). The RR
interval was automatically analyzed statistically as a function
of time (time domain analysis) by the Pathfinder using a
commercially available and validated software program
(Reynolds Medical Software version 4.63). The following
time-domain indices were evaluated: standard deviation of
all RR intervals, 24 h triangle index, standard deviation of
5-min mean RR intervals and the root mean square of
differences of successive RR intervals.
Frequency domain (power spectral) analysis was under-
taken by fast Fourier transformation. This process operated
on data of 5 min segments of each hour over the 24-h
recording while the subjects were at rest. Time periods
where there were excessive movements were excluded.
Spectral plots were used to identify the low-frequency (LF)
component (0.03 to 0.14 Hz) and the high-frequency (HF)
component (0.18 to 0.40 Hz). Indices are expressed in
normalized units (n.u.), or the relative percentage compared
to the total oscillatory power.
Recordings shorter than 18 h or with ,40% of the tape
suitable for analysis were discarded. Separate analyses were
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CHF 5 chronic heart failure
CQTc 5 corrected QT dispersion
ECG 5 electrocardiogram
HF 5 high frequency
HPLC 5 high-performance liquid chromatography
HRV 5 heart rate variability
LF 5 low frequency
MIBG 5 metaiodobenzylguanidine
NA 5 norepinephrine
NYHA 5 New York Heart Association
QTd 5 QT interval dispersion
RALES 5 Randomized Aldactone Evaluation Study
SCD 5 sudden cardiac death
Table 1. Baseline Demographic Characteristics of
Randomized Patients
Characteristics n 5 28
Age (yrs) 63 6 9*
M/F 24/4
Weight (kg) 75 6 12
Etiology of CHF
Ischemic 23 (82%)
Idiopathic dilated cardiomyopathy 3 (11%)
Unknown 2 (7%)
LVEF (%) 29 6 7
NYHA
Class II 15 (54%)
Class III 13 (46%)
Furosemide 25 (89%)
ACE inhibitor 28 (100%)
Ca antagonist 6 (21%)
Aspirin 21 (75%)
Nitrates 15 (54%)
Beta-blockers 2 (7%)
Digoxin 8 (29%)
History of diabetes mellitus 6 (21%)
History of hypertension 3 (11%)
*Mean 6 standard deviation.
ACE 5 angiotensin-converting enzyme; CHF 5 chronic heart failure; LVEF 5
left ventricular ejection fraction; NYHA 5 New York Heart Association.
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undertaken for the dawn period (0600 h to 1000 h) and the
rest of the day (1000 h to 0600 h). These times were
specified before the study began, as our hypothesis was that
the dawn period might be different from the rest. All
analyses were carried out by a single observer (KMY) blind
to conditions. The intra-observer variability for HRV anal-
ysis was 6% to 7% for power spectral analyses and 5% to 6%
for time-domain indices.
QT interval and dispersion analysis. QT interval analysis
was performed on ECGs (with simultaneous 12-lead acqui-
sition) recorded with a Hewlett-Packard 4700A electrocar-
diogram machine (Palo Alto, California). All QT intervals
and dispersion (QTd) were analyzed blindly on a Calcomp
digitizing tablet (Twyford, United Kingdom) using custom-
ized software (Medical Computing Unit, Ninewells Hospi-
tal). QT interval was taken from the onset of the QRS to
the end of the T wave (i.e., return to the T/P baseline). If U
waves were present, the QT interval was measured to the
nadir of the curve between the T and U waves. Three
consecutive cycles were usually measured for each lead. QT
intervals were corrected with Bazett’s formula (QTc5
QT/RR1/2).
QTd was calculated in ECGs in which $9 leads were
measurable. QTd is defined as the difference between
maximum and minimum QT intervals (QTd 5 QTmax 2
QTmin). Corrected QT dispersion (QTcd) is defined as the
difference between maximum and minimum QTc (QTcd 5
QTcmax 2 QTcmin). The intra-observer variability was 3%
and 8% to 9% for measurements of QT intervals and QT
dispersion, respectively.
Norepinephrine kinetics. Studies were performed accord-
ing to the well-established technique of Esler et al. (23). An
initial loading dose of tritiated NA infusion (NEN-
DuPont, Herts, United Kingdom) was given intravenously
as a bolus (12.5 mCi over 2 min) followed by a constant
infusion (0.7 mCi/min/m2) for 60 min. This infusion
protocol has been shown to achieve constant plasma con-
centration of tritiated NA within 30 min (24). Venous
blood samples (20 ml) were taken for determination of
resting plasma NA and tritiated NA levels after 40 and
50 min infusion (two samples were taken to ensure that
steady state had been achieved). Blood samples were taken
in chilled lithium-heparin tubes centrifuged at 3,000 rpm at
4°C, and the plasma was separated and stored at 270°C
until assayed as a batch. Two 5 ml samples of the infusate
were also collected (one before and the other after comple-
tion of infusion), stored and assayed as described for the
blood samples, to allow determination of the actual rate of
tritiated NA infusion.
After the addition of dihydroxybenzylamine used as an
internal standard, catechols were extracted through adsorp-
tion on alumina. After elution from the alumina through
the addition of 0.2 mol/L HClO4, the catechols were then
separated and measured by high-performance liquid chro-
matography (HPLC). The HPLC effluent coinciding with
the NA peak was collected, and (3H)NA radioactivity levels
were determined by liquid scintillation spectroscopy. The
intra-assay coefficient of variability was 6.1%. Norepineph-
rine kinetics are calculated as follows:
Whole body NA clearance 5
@3H#NA infusion rate ~dpm/min!
Plasma @3H#NA concentration ~dpm/ml!
Whole body NA spillover 5
@3H#NA infusion rate ~dpm/min!
Specific radioactivity of plasma NA ~dpm/pg!
Statistical analysis. All the data were analyzed using Stat-
graphics software package (STSC Software Publishing
Group, Maryland). Repeated measures analysis of variance
was carried out on the HRV and QT outcome measures.
The within-subject factors were treatment and time; the
between-subject factor was order of treatment. A full
factorial model was fitted to test the significance of these
factors. The effects of treatment on the other measures were
analyzed using the paired Student t test. A p value , 0.05
was regarded as significant.
RESULTS
Both spironolactone and placebo given in addition to ACE
inhibitors were well tolerated. There were no significant
changes in baseline hemodynamic parameters. After four
weeks of treatment, spironolactone caused a small but
significant rise in plasma potassium and magnesium (Table
2). Three of the patients had significant hyperkalemia
(potassium .5.5 mmol/l) and elevation of plasma creatinine
(.300 mmol/l), which necessitated the dose of spironolac-
tone to be halved (25 mg). Plasma aldosterone levels
measured between 6 AM and 11 AM rose from 90 6 39 pg/ml
to 137 6 60 pg/ml and from 220 6 80 pg/ml to 316 6
108 pg/ml on the placebo and spironolactone study days,
respectively. The effects of spironolactone on the various
autonomic indices are displayed in Tables 2 and 3. Arrhyth-
mic activity was unaffected.
Circadian pattern of heart rate variability. Spironolac-
tone therapy caused a significant overall increase in the
mean HF component and decrease in the LF/HF ratio
throughout the 24-h period compared to placebo (Table 2).
There was also a highly significant time and treatment
interaction for these measures. The effects on the HRV
indices were greatest from 0600 to 1000 (Table 3, Figs. 1
and 2). During these hours, standard deviation of the RR
intervals and the HF component were significantly in-
creased, whereas both heart rate and the LF/HF ratio were
reduced. The LF component was not significantly affected.
Circadian pattern of QT dispersion. QT interval disper-
sion indices were significantly higher during the day com-
pared with the sleeping hours (Fig. 3). All measured QT
indices including QTcmax and QTd were significantly
reduced by spironolactone (Table 2, Fig. 4). In addition,
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there were also significant time and treatment interactions
for these outcome measures, with the treatment effects of
spironolactone greatest during the morning hours.
Norepinephrine kinetics. There were no significant dif-
ferences in the diurnal profile of plasma NA levels between
the two treatments. Whole-body NA clearance and spillover
did not appear to be significantly affected by spironolactone
therapy compared with placebo (Table 3).
Subgroup analyses. There were no significant differences
in treatment effects between NYHA classes or between the
NIDDM and non-NIDDM subgroups. It must however be
pointed out that the study was not designed (and therefore
was not statistically “powered”) for subgroup analyses.
DISCUSSION
Consistent with previous findings (6,10,24,25), the addition
of a small dose of spironolactone (50 mg/daily) to mainte-
nance treatment with a loop diuretic and ACE inhibitor in
CHF appears to be well tolerated. Spironolactone improved
not only heart rate itself but also HRV and QT dispersion.
Perhaps the most intriguing aspect of our findings is that
Table 2. Mean 24-h Values: Effect of Spironolactone or Placebo on Various Biochemical, Hemodynamic and Autonomic Indices
Parameter Placebo Spironolactone p Value
Biochemical and hemodynamic measures HR (beats/min) 72 6 13* 70 6 12 NS
SBP (mm Hg) 125 6 20 121 6 18 NS
K1 (mmol/l) 3.9 6 0.4 4.3 6 0.4 0.01
Urea (mmol/l) 7.6 6 3.5 8.8 6 4.1 0.01
Mg21 (mmol/l) 0.82 6 0.05 0.85 6 0.06 0.05
Time-domain measures RR Int 771 6 122 798 6 143 0.006
HRV index 27 6 10 27 6 8 NS
SDNN 91 6 32 92 6 26 NS
SDANN 81 6 30 82 6 23 NS
RMSSD 20 6 11 21 6 8 NS
Frequency (power spectal) measures LF (n.u.) 69.5 6 16.5 67.7 6 17.1 NS
HF (n.u.) 21.8 6 14.7 24.6 6 16.8 0.001
LF/HF 4.98 6 3.54 4.40 6 3.10 0.006
24-h arrhythmia analysis Ventricular extrasystoles/24 h 2240 6 2125 2425 6 4555 NS
NSVT (no. patients) 3 1 NS
QT interval and dispersion variables QTd 66.6 6 12.3 58.2 6 7.7 0.003
QTcd 73.2 6 13.4 65.3 6 7.6 0.0001
QTmax 468 6 26 456 6 24 0.017
QTcmax 480 6 34 467 6 30 0.001
*Mean 6 standard deviation.
HF 5 high frequency; HR 5 heart rate; HRV 5 heart rate variability; LF 5 low frequency; NS 5 nonsignificant; NSVT 5 nonsustained ventricular tachycardia; n.u. 5
normalized units; RMSSD 5 root mean square of differences of successive RR intervals; SBP 5 systolic blood pressure; SDANN 5 standard deviation of 5-min mean RR
intervals; SDNN 5 standard deviation of all RR intervals.
Table 3. Diurnal Effects of Spironolactone and Placebo on Autonomic Indices
Indices Time (h) Placebo Spironolactone
p Value
Treatment*
Treatment
and Time
Interaction*
RR (ms) 0600–1000 h 785 6 154† 821 6 161 0.006
0.013
1000–0600 h 775 6 148 801 6 160
SDRR (ms) 0600–1000 h 61 6 30 71 6 31
0.010 0.009
1000–0600 h 53 6 33 53.9 6 27
HRV indices LF (n.u.) 0600–1000 h 71 6 18 67 6 16
0.267 0.893
1000–0600 h 69 6 17 68 6 18
HF (n.u.) 0600–1000 h 20 6 14 27 6 18
, 0.0001 0.016
1000–0600 h 22 6 15 24 6 19
LF/HF 0600–1000 h 5.62 6 4.01 4.01 6 2.76
0.006 0.037
1000–0600 h 4.82 6 3.65 4.47 6 3.42
NA kinetics NA clear. (l/min) am (0700 h) 3.41 6 1.0 3.35 6 0.8 NS
NA spil. (mg/min) 1.50 6 0.65 1.71 6 0.35 NS
NA clear. (l/min) pm (1600 h) 3.32 6 0.8 3.0 6 0.7 NS
NA spil. (mg/min) 1.75 6 0.82 1.83 6 0.63 NS
*Based on repeated measure analysis of variance full factorial model. †Mean 6 standard deviation.
HF 5 high frequency; HRV 5 heart rate variability; LF 5 low frequency; NA 5 norepinephrine.
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these effects appear to be maximal between 6 AM and 10 AM
when aldosterone secretion is also maximal (12,13). It is
unlikely that the observed heightened early morning effect
of spironolactone can be attributed to the drug pharmaco-
kinetics, as spironolactone has a very gradual and prolonged
action (26). Furthermore the observed beneficial effects were
observed from 6 AM onwards, well before the patients took
the study medications (8–9 AM).
Aldosterone and circadian sympathovagal modulation.
To date, there have been very limited data regarding the
diurnal variation of the autonomic tone in CHF. Spectral
analysis of 24-h HRV recordings has shown that in normal
subjects, LF and HF indices exhibit a circadian pattern and
reciprocal fluctuations with higher values of LF in the
daytime and of HF at night, corresponding with a sympa-
thetic predominance during the day and vagal predomi-
nance during the night (15).
In CHF, this normal circadian variation of the autonomic
tone is disrupted. Both time-domain and frequency-domain
parameters of HRV are reduced (14,27–29). Reduced HRV
has recently been shown to be a good predictor of SCD in
CHF (30). In our study, we observed a reduced but still
preserved circadian pattern in the spectral components in
CHF, a finding also reported by some (14) but not others
(28,29).
We found that the circadian variation of the autonomic
tone is further improved or preserved following spironolac-
tone therapy. In particular, the HF spectral component was
significantly increased whereas the LF/HF ratio was signif-
icantly reduced during the morning hours (6–10 AM).
Interestingly, heart rate was also significantly reduced dur-
ing this crucial time period, a finding that we had observed
in another study (11).
Vagal activity is thought to be the major contributor to
Figure 1. Diurnal variation of RR intervals (RR Int) (top) and ratio of
low-frequency to high-frequency component (LF/HF) of heart rate vari-
ability (bottom). Data expressed as mean 6 SEM. Open circles 5
placebo; solid triangles 5 spiro.
Figure 2. Diurnal variation of normalized high-frequency component
(HF) (top) and normalized low-frequency component (LF) (bottom) of
heart rate variability. Data expressed as mean 6 SEM. Open circles 5
placebo; solid triangles 5 spiro.
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the HF component (22). Whereas some studies suggest that
LF, when expressed as n.u., is a quantitative marker for
sympathetic modulations, others view LF as reflecting both
sympathetic and vagal activity (22). Consequently, the
LF/HF ratio is considered by some to mirror sympathovagal
balance (22). Thus the favorable impact of spironolactone
on both HF and LF/HF (but not LF) suggests that it works
predominantly on the vagal limb of the autonomic tone.
There is certainly a growing body of evidence that aldoste-
rone has detrimental effects on vagal activity (7,8).
The role of aldosterone in sympathetic modulation is
controversial. Although there is some evidence to suggest
that aldosterone may potentiate sympathetic activity
(10,11), we were unable to confirm this. The diurnal plasma
NA profiles were similar with both treatments, and whole-
body NA kinetics was unaffected. These findings are not
necessarily a contradiction to previous observations where
cardiac NA uptake as assessed by MIBG scanning was
increased by spironolactone (10). The sympathetic nervous
system is highly differentiated, and the effects observed in
the body as a whole may not be representative of adrenergic
drive specifically to the heart (31). Newton et al. (32) made
similar observations with digoxin therapy in CHF when
they found that digoxin reduced cardiac NA spillover but
did not affect total-body NA kinetics.
Aldosterone and QT dispersion. The circadian pattern of
the QTc interval and dispersion in normal humans is well
established (33,34), but we believe that ours is the first study
to show that QT dispersion occurs in a circadian fashion in
patients with CHF. Following spironolactone treatment,
both QTcmax and QT dispersion were significantly reduced
at nearly all time points (Table 3, Fig. 4). This effect was
greatest in the morning hours where there was a 19%
reduction in QTd compared to placebo. Even more impor-
tant is that of the six patients who had a QTd . 80 ms on
placebo, none of them had a QTd . 80 ms on spironolac-
tone. QTc interval prolongation has repeatedly been shown
to be an independent risk factor for SCD (35–37). Similarly,
QTd . 80–85 ms has been identified as a crucial threshold
in predicting SCD (37). QTd is thought to be a measure of
electrical inhomogeneity, which decreases an individual
threshold for ventricular arrhythmias (38). These data
would suggest that spironolactone may have properties that
reduce malignant arrhythmias. Although arrhythmic events
were not significantly influenced in this study, the sample
size and the number of potentially lethal arrhythmic events
recorded were small.
There are a number of possible mechanisms in which
aldosterone may contribute to prolongation and dispersion
of the QT interval. As our HRV data suggest, aldosterone
may have detrimental autonomic modulating properties,
and the only drugs to have reduced QTd are those that
modulate the autonomic tone, such as beta-blockers (39,40)
and ACE inhibitors (41–43). Aldosterone-induced potas-
sium and magnesium depletion may also contribute to
dispersion of the QT intervals. Both hypokalemic and
hypomagnesemic states are arrhythmogenic, associated with
prolongation of the QT intervals and increased likelihood of
developing ventricular arrhythmias (44–46). Conversely,
magnesium replacement shortens the QT interval and has
been shown to be effective in terminating torsade de pointes
(47). The effects of magnesium on QT dispersion are
unknown. Potassium is one of the main determinants of the
QT interval, as it is responsible for the outward repolariza-
tion currents. Hypokalemia results in slower repolarization
and prolonged QT intervals (48). Recently, Choy et al. (49)
observed that intravenous potassium infusion not only
normalized QT prolongation but also reduces QT disper-
sion in CHF.
Study limitations. First, the technical difficulty of obtain-
ing a precise and reproducible determination of the QT
interval is well recognized. Care has been taken to use
consistent criteria to define the end of the T wave and to
exclude U waves. In any case, this was not a major issue for
this study as we were looking at treatment-induced intra-
Figure 3. Diurnal variation of QT dispersion (QTd). Data expressed as
mean 6 SEM. Solid triangles 5 spiro; solid circles 5 placebo.
Figure 4. Individual mean 24-h QTc dispersion (QTc Disp) data: the
effects of spironolactone (Spiro) and placebo on QTc Disp.
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individual changes in QTd. Second, only a minority of
subjects in this trial were on beta-blockers. This reflects
current practice in the United Kingdom. Although beta-
blockers could alter the autonomic tone, many patients with
CHF cannot tolerate them. In any case, the main effect of
beta-blocker therapy is on the sympathetic system, whereas
the main effect of spironolactone appears to be on the
parasympathetic tone. Hence, the use of both treatments
may actually be synergistic in reducing mortality, as sug-
gested by the RALES subgroup analysis (6).
Conclusions. Aldosterone blockade has a number of ben-
eficial effects in CHF. It reduces heart rate and improves the
parasympathetic component of HRV and QT dispersion.
Its effects appear to be greatest during the morning hours,
coinciding with the circadian pattern of cardiac events.
Reprint requests and correspondence: Dr. K. M. Yee, Cardiac
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